Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma
Conditions
Lymphoma
Conditions: official terms
Lymphoma
Study Type
Interventional
Study Phase
Phase 2
Study Design
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: GemDOx
Type: Drug
Overall Status
Recruiting
Summary
- To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)
Detailed Description
- The feasibility will be evaluated in terms of objective response rate, efficacy of stem cell collection, disease-free survival, and overall survival.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 65 Years
Minimum Age: 15 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients who have refractory to first-line CHOP-like regimen

- Patients who have first relapse after

- first-line CHOP-like regimen

- upfront autologous or allogeneic hematopoietic stem cell transplantation

- Age 15 years or more

- ECOG performance status ≤ 2

- Adequate bone marrow function

- Adequate kidney,liver,cardiac

Exclusion Criteria:

- Patients who have received GEM or OX
Location
Asan Medical Center
Seoul, Korea, Republic of
Status: Recruiting
Contact: Yae-Eun Jang, nurse - 82-2-3010-7290 - redpin75@naver.com
Start Date
November 2006
Completion Date
October 2009
Sponsors
Cooperative Study Group A for Hematology
Source
Cooperative Study Group A for Hematology
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page